comparemela.com
Home
Live Updates
Lirafugratinib Elicits Durable Responses Across Several FGFR
Lirafugratinib Elicits Durable Responses Across Several FGFR
Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors
Lirafugratinib demonstrated clinical activity in multiple subsets of patients with FGFR2-altered solid tumors, including those with FGFR2-altered hormone receptor–positive, HER2-negative breast cancer.
Related Keywords
,
Sloan Kettering ,
Alisonm Schram ,
Don Bergstrom ,
International Conference On Molecular ,
Molecular Targets ,
Relay Therapeutics ,
Memorial Sloan Kettering ,
Bayesian Optimal Interval ,
Precision Medicine In Oncology ,
News ,
Nct04526106 ,
2023 Aacr Nci Eortc International Conference On Molecular Targets And Cancer Therapeutics ,